Clinical Study

β-Thalassemia Intermedia in Northern Iraq: A Single Center Experience

Table 1

Genotype, clinical, and hematological parameters in 74 patients with TI enrolled in the current study.

NumberFamily -GenotypeXmn I status -GenotypeAge
(yr)
SexAge at diagnosis (yr)Age at first Tx. Number of Tx. last yr.Spleen cm BCMHb (g/dL) (%) (%)

1F1IVS-I-6/IVS-I-6−/−α α/α α20F88057.57.18.7
2F1IVS-I-6/IVS-I-6−/−α α/α α21M10100S8.08.411.1
3F2IVS-I-6/IVS-I-6−/−α α/α α7M4NT037.06.98.7
4F2IVS-I-6/IVS-I-6−/−α α/α α9F7NT037.66.114.9
5F3IVS-I-6/IVS-I-6−/−α α/α α13M512138.16.624.5
6F4IVS-I-6/IVS-I-6−/−α α/α α19F44237.55.817.6
7F4IVS-I-6/IVS-I-6−/−α α/α α21M44149.17.08.3
8F5IVS-I-6/IVS-I-6−/−α α/α α38F24244S9.38.010.0
9F6IVS-I-6/IVS-I-6−/−α α/α α27F426057.86.810.4
10F6IVS-I-6/IVS-I-6−/−α α/α α33M550S8.28.57.7
11F7IVS-I-6/IVS-I-6−/−α α/α α10F8NT017.37.29.8
12F7IVS-I-6/IVS-I-6−/−α α/α α11F10NT017.36.412.3
13F7IVS-I-6/IVS-I-6−/−α α/α α7F5NT0NP7.46.213.0
14F8IVS-I-6/IVS-I-6−/−α α/α α5M11237.84.517.3
15F9IVS-I-6/IVS-I-6−/−α α/α α4M3 mNT027.64.836.3
16F10IVS-I-6/IVS-I-6−/−α α/α α3.0M3NT0210.64.232.5
17F11IVS-I-6/IVS-I-6−/−α α/α α31F661239.1NANA
18F12IVS-I-6/IVS-I-6−/−α α/α α7F5NT077.27.329.4
19F12IVS-I-6/IVS-I-6−/−α α/α α15M55076.8726.9
20F13IVS-I-128/IVS-I-128−/−α α/α α24M11NT018.6725
21F13IVS-I-128/IVS-I-128−/−α α/α α21F55317.9535
22F14 −28/−28−/−α α/α α33M1515267.6718.5
23F15IVS-1-6/−30 (T>A)−/−α α/α α33F11110S8.3520
24F16IVS-I-6/IVS-II-1+/−α α/α α8M7.5NT049.23.965.7
25F17IVS-I-6/IVS-II-1+/−α α/α α10M10NT028.3362.2
26F18IVS-I-6/Cd 82/83+/−α α/α α6F9 m5127.72.854.2
27F18IVS-I-6/Cd 82/83+/−α α/α α4M9 mNT018.11.545.5
28F18IVS-I-6/Cd 82/83+/−α α/α α3F3NT028.32.060
29F18IVS-I-6/Cd 82/83+/−α α/α α13F661018.92.8*45*
30F19IVS-I-6/Cd 39−/−α α/α α5F6 m2138.03.556.0
31F20IVS-I-6/Cd 5−/−α α/α α46F34400S7.85.187.2
32F20IVS-I-6/Cd 5−/−α α/α α49F37420S7.2880.1
33F21IVS-1-6/Cd 8+/−α α/α α25F2424878.03.3*58*
34F22IVS-I-6/Cd 8+/−α α/α α2.5F2.52.5126.95.546.6
35F22IVS-I-6/Cd 8+/−α α/α α13F5512S9.6NANA
36F22IVS-I-6/Cd 8+/−α α/α α5F44247.26.148
37F23IVS-1-6/IVS-I-1−/−α α/α α29F6612S10.6NANA
38F24IVS-I-130/Poly A−/−α α/α α32M88076.5346
39F25 Cd 5/Poly A+/−α α/α α16M333774.235.4
40F25Cd 5/Poly A+/−α α/α α18M330S6.75.737.9
41F25Cd 5/Poly A+/−α α/α α7F33446.84.033.9
42F25Cd 5/Poly A+/−α α/α α22F220S7.96.435.4
43F25Cd 5/Poly A+/−α α/α α8F6NT027.13.849.1
44F26Cd 5/Poly A+/−α α/α α23F55048.66.141.6
45F26Cd 5/Poly A+/−α α/α α36F1717037.36.637.1
46F26Cd 5/Poly A+/−α α/α α19M77037.46.336.8
47F27IVS-II-1/IVS-II-1+/+α α/α α19M1NT0S9.51.598.5
48F27IVS-II-1/IVS-II-1+/+α α/α α8M1NT0S9.3396
49F28IVS-II-1/IVS-II-1+/+α α/α α14M10NT04113.596.5
50F28IVS-II-1/IVS-II-1+/+α α/α α17F331511.64.096
51F29IVS-II-1/IVS-II-1+/+α α/α α7F44067.51.896.3
52F30IVS-II-1/IVS-II-1+/+α α/α α18M16NT02102.697
53F31Cd 82/83/Cd 82/83+/+α α/α α29M994S9.92.791.7
54F32Cd 82/83/Cd 82/83+/+α α/α α26M550107.62.597.5
55F33Cd 82/83/Cd 82/83+/+α α/α α25M19190111.01.698.3
56F34Cd 82/83/Cd 82/83+/+α α/α α8M2.52.5047.33.895
57F35Cd 8/Cd 8+/+α α/α α19F773S9.42.094
58F36IVS-II-1/Cd 82/83+/+α α/α α9M11539.54.7*95.0*
59F37IVS-II-1/Cd 8+/+α α/α α7M7NT037.5298
60F38Cd 8/IVS-II-1+/−α α/α α12M551226.92.5*97.5*
61F38Cd 8/IVS-II-1+/−α α/α α5F9 mNT018.72.098
62F39IVS-II-1/Cd 44+/−α α/α α5F22.5228.11.898.2
63F40IVS-II-1/Cd 44+/− /α α18M2NT029.72.397.7
64F41IVS-II-1/IVS-I-1+/−α α/α α3M8 mNT0NP7.4396.8
65F42IVS-II-1/IVS-I-1+/− /α α5M441016.72*98*
66F43Cd 8/IVS-I-110+/− /α α21M110S10587
67F44IVS-II-1/IVS1-110+/−α α/α α12M55278.32.955
68F45Cd 8/IVS-I-1+/−α α/α α4M24117.71.698
69F46IVS-II-1/IVS-II-1+/− /α α18F6603102.797.3
70F47IVS-I-130/Cd 5−/−α α/α α16F220S9.62.597.4
71F48IVS-II-1/IVS-1-130+/−α α/α α20F3NT0S8.3595
72F49Cd 5/Wild−/−α α/α α8F2NT036.95.85.7
73F50Cd 5/Wild−/−α α/α αα17F1313456.54.53.3
74F51Cd 39/Wild−/−α α/α α30M19191194.98.8

NA: Not Available; NP: Not Palpable; *Parameter at diagnosis; S: Splenectomy; NT: never transfused; M: Male; F: Female; Poly A: AATAAA>AATAAG mutation; Tx: transfusion.